KOD - Kodiak Sciences Inc.

3.77
-0.230   -6.101%

Share volume: 257,127
Last Updated: 05-09-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$4.00
-0.23
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
32%
Profitability 35%
Dept financing 15%
Liquidity 43%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.58%
1 Month
72.94%
3 Months
-8.94%
6 Months
-8.94%
1 Year
-8.94%
2 Year
-8.94%
Key data
Stock price
$3.77
P/E Ratio 
0.00
DAY RANGE
$3.74 - $4.16
EPS 
-$0.83
52 WEEK RANGE
$1.92 - $5.14
52 WEEK CHANGE
-$8.94
MARKET CAP 
523.607 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$531,545
AVERAGE 30 VOLUME 
$484,407
Company detail
CEO: Victor Perlroth
Region: US
Website: kodiak.com
Employees: 90
IPO year: 2018
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) The company was formerly known as Oligasis, LLC.

Recent news
loading